Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × INDUSTRY × 3-ingenyl angelate × Clear all

Phase

Status

Completed 36 Withdrawn 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Interventions

Paclitaxel 30 Cisplatin 26 Cyclophosphamide 25 Carboplatin 25 Bevacizumab 22 Nivolumab 19 pembrolizumab 18 Docetaxel 18 Rituximab 17 Fluorouracil 17 Gemcitabine 15 Dexamethasone 15 avelumab 14 Leucovorin 13 Ipilimumab 11 Capecitabine 11 fludarabine 10 atezolizumab 10 Cetuximab 10 130-nm albumin-bound paclitaxel 10 venetoclax 9 Radiotherapy 9 ALT-803 9 Pemetrexed 8 trametinib 7 Radiosurgery 7 Prednisone 7 Oxaliplatin 7 Lenalidomide 7 Bendamustine Hydrochloride 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00546611 2016-01-28

The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)

Peplin

Phase 1 Withdrawn

Warts

Data powered by HemOnc (CC BY 4.0) Colophon ⚡